A

n update to my column yesterday about Aerie Pharmaceuticals (AERI) and what I called an under-appreciated manufacturing risk related to its glaucoma drug Rhopressa, now under review at the FDA.

It now looks like I over-appreciated the Rhopressa manufacturing challenge.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Get rid of short shill Adam FEURSTEIN Or lose business

    This guy is a known basher of great companies
    He’s a shill for short hedge funds

    Why didn’t you check his background?

    STAT better be smart

    You guys are gonna lose subscribers

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X